Tags

Type your tag names separated by a space and hit enter

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
J Infect Dis. 2008 Jun 01; 197(11):1577-84.JI

Abstract

BACKGROUND

In 1999-2000, reports of fatalities after vaccination with 17D-derived yellow fever vaccine (YEL) focused mainly on cases of YEL-associated adverse events (YEL-AEs) and YEL-associated viscerotropic disease (YEL-AVD). Here, we investigated 6 recent European cases to provide insight regarding immune response involvement and to identify potential risk factors.

METHODS

Clinical, microbiological, molecular biological, and immunological assays were performed on serum from 6 patients with YEL-AEs, including 5 with YEL-AVD and 1 with YEL-associated neurotropic disease (YEL-AND).

RESULTS

The levels of 3 liver enzymes associated with infection were clearly increased in all patients with YEL-AVD, but no elevations were observed in the patient with YEL-AND. In the patients with severe YEL-AVD, platelet counts were markedly reduced (< 100,000 cells/microL). The only patient with fatal YEL-AVD exhibited a cytokine profile comparable to that seen in YF: high levels of interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1, monokine induced by interferon-gamma, and growth-related oncogene (GRO). The other patients with YEL-AVD exhibited similar but less severe cytokine profiles. The patient with YEL-AND exhibited a cytokine profile similar to that found in vaccinees without YEL-AEs: elevated levels of RANTES and low levels of GRO, MCP-1, transforming growth factor-beta1, and tumor necrosis factor-beta.

CONCLUSIONS

On the basis of these results, we conclude that elevations in cytokine levels and reductions in platelet counts are suitable surrogate markers for patients likely to experience severe adverse reactions to YEL.

Authors+Show Affiliations

Robert Koch-Lnstitut, Berlin, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18419548

Citation

Bae, Hi-Gung, et al. "Immune Response During Adverse Events After 17D-derived Yellow Fever Vaccination in Europe." The Journal of Infectious Diseases, vol. 197, no. 11, 2008, pp. 1577-84.
Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis. 2008;197(11):1577-84.
Bae, H. G., Domingo, C., Tenorio, A., de Ory, F., Muñoz, J., Weber, P., Teuwen, D. E., & Niedrig, M. (2008). Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. The Journal of Infectious Diseases, 197(11), 1577-84. https://doi.org/10.1086/587844
Bae HG, et al. Immune Response During Adverse Events After 17D-derived Yellow Fever Vaccination in Europe. J Infect Dis. 2008 Jun 1;197(11):1577-84. PubMed PMID: 18419548.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. AU - Bae,Hi-Gung, AU - Domingo,Cristina, AU - Tenorio,Antonio, AU - de Ory,Fernando, AU - Muñoz,José, AU - Weber,Paul, AU - Teuwen,Dirk E, AU - Niedrig,Matthias, PY - 2008/4/19/pubmed PY - 2008/9/5/medline PY - 2008/4/19/entrez SP - 1577 EP - 84 JF - The Journal of infectious diseases JO - J Infect Dis VL - 197 IS - 11 N2 - BACKGROUND: In 1999-2000, reports of fatalities after vaccination with 17D-derived yellow fever vaccine (YEL) focused mainly on cases of YEL-associated adverse events (YEL-AEs) and YEL-associated viscerotropic disease (YEL-AVD). Here, we investigated 6 recent European cases to provide insight regarding immune response involvement and to identify potential risk factors. METHODS: Clinical, microbiological, molecular biological, and immunological assays were performed on serum from 6 patients with YEL-AEs, including 5 with YEL-AVD and 1 with YEL-associated neurotropic disease (YEL-AND). RESULTS: The levels of 3 liver enzymes associated with infection were clearly increased in all patients with YEL-AVD, but no elevations were observed in the patient with YEL-AND. In the patients with severe YEL-AVD, platelet counts were markedly reduced (< 100,000 cells/microL). The only patient with fatal YEL-AVD exhibited a cytokine profile comparable to that seen in YF: high levels of interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1, monokine induced by interferon-gamma, and growth-related oncogene (GRO). The other patients with YEL-AVD exhibited similar but less severe cytokine profiles. The patient with YEL-AND exhibited a cytokine profile similar to that found in vaccinees without YEL-AEs: elevated levels of RANTES and low levels of GRO, MCP-1, transforming growth factor-beta1, and tumor necrosis factor-beta. CONCLUSIONS: On the basis of these results, we conclude that elevations in cytokine levels and reductions in platelet counts are suitable surrogate markers for patients likely to experience severe adverse reactions to YEL. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/18419548/Immune_response_during_adverse_events_after_17D_derived_yellow_fever_vaccination_in_Europe_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/587844 DB - PRIME DP - Unbound Medicine ER -